These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 31106910)

  • 1. Microglia suppress the secondary progression of autoimmune encephalomyelitis.
    Tanabe S; Saitoh S; Miyajima H; Itokazu T; Yamashita T
    Glia; 2019 Sep; 67(9):1694-1704. PubMed ID: 31106910
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of relapsing-remitting and chronic forms of experimental autoimmune encephalomyelitis in C57BL/6 mice.
    Berard JL; Wolak K; Fournier S; David S
    Glia; 2010 Mar; 58(4):434-45. PubMed ID: 19780195
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased expression of colony-stimulating factor-1 in mouse spinal cord with experimental autoimmune encephalomyelitis correlates with microglial activation and neuronal loss.
    Gushchina S; Pryce G; Yip PK; Wu D; Pallier P; Giovannoni G; Baker D; Bo X
    Glia; 2018 Oct; 66(10):2108-2125. PubMed ID: 30144320
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interleukin-33 deficiency exacerbated experimental autoimmune encephalomyelitis with an influence on immune cells and glia cells.
    Xiao Y; Lai L; Chen H; Shi J; Zeng F; Li J; Feng H; Mao J; Zhang F; Wu N; Xu Y; Tan Z; Gong F; Zheng F
    Mol Immunol; 2018 Sep; 101():550-563. PubMed ID: 30173119
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dual roles of the adenosine A2a receptor in autoimmune neuroinflammation.
    Ingwersen J; Wingerath B; Graf J; Lepka K; Hofrichter M; Schröter F; Wedekind F; Bauer A; Schrader J; Hartung HP; Prozorovski T; Aktas O
    J Neuroinflammation; 2016 Feb; 13():48. PubMed ID: 26920550
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activation of Glucagon-Like Peptide-1 Receptor Promotes Neuroprotection in Experimental Autoimmune Encephalomyelitis by Reducing Neuroinflammatory Responses.
    Lee CH; Jeon SJ; Cho KS; Moon E; Sapkota A; Jun HS; Ryu JH; Choi JW
    Mol Neurobiol; 2018 Apr; 55(4):3007-3020. PubMed ID: 28456941
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neurodegeneration progresses despite complete elimination of clinical relapses in a mouse model of multiple sclerosis.
    Hampton DW; Serio A; Pryce G; Al-Izki S; Franklin RJ; Giovannoni G; Baker D; Chandran S
    Acta Neuropathol Commun; 2013 Dec; 1():84. PubMed ID: 24364862
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sphingosine 1-phosphate receptor modulation suppresses pathogenic astrocyte activation and chronic progressive CNS inflammation.
    Rothhammer V; Kenison JE; Tjon E; Takenaka MC; de Lima KA; Borucki DM; Chao CC; Wilz A; Blain M; Healy L; Antel J; Quintana FJ
    Proc Natl Acad Sci U S A; 2017 Feb; 114(8):2012-2017. PubMed ID: 28167760
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibiting repulsive guidance molecule-a suppresses secondary progression in mouse models of multiple sclerosis.
    Tanabe S; Fujita Y; Ikuma K; Yamashita T
    Cell Death Dis; 2018 Oct; 9(11):1061. PubMed ID: 30333477
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Microglial and astroglial reactions to inflammatory lesions of experimental autoimmune encephalomyelitis in the rat central nervous system.
    Matsumoto Y; Ohmori K; Fujiwara M
    J Neuroimmunol; 1992 Mar; 37(1-2):23-33. PubMed ID: 1372328
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Loss of Nrf2 exacerbates the visual deficits and optic neuritis elicited by experimental autoimmune encephalomyelitis.
    Larabee CM; Desai S; Agasing A; Georgescu C; Wren JD; Axtell RC; Plafker SM
    Mol Vis; 2016; 22():1503-1513. PubMed ID: 28050123
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improved clinical behavior of established relapsing-remitting experimental autoimmune encephalomyelitis following treatment with endogenous opioids: implications for the treatment of multiple sclerosis.
    Hammer LA; Zagon IS; McLaughlin PJ
    Brain Res Bull; 2015 Mar; 112():42-51. PubMed ID: 25647234
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Opioid growth factor and low-dose naltrexone impair central nervous system infiltration by CD4 + T lymphocytes in established experimental autoimmune encephalomyelitis, a model of multiple sclerosis.
    Hammer LA; Waldner H; Zagon IS; McLaughlin PJ
    Exp Biol Med (Maywood); 2016 Jan; 241(1):71-8. PubMed ID: 26202376
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RAE-1 expression is induced during experimental autoimmune encephalomyelitis and is correlated with microglia cell proliferation.
    Djelloul M; Popa N; Pelletier F; Raguénez G; Boucraut J
    Brain Behav Immun; 2016 Nov; 58():209-217. PubMed ID: 27444966
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neuroimmunological characterization of a mouse model of primary progressive experimental autoimmune encephalomyelitis and effects of immunosuppressive or neuroprotective strategies on disease evolution.
    Buonvicino D; Ranieri G; Pratesi S; Guasti D; Chiarugi A
    Exp Neurol; 2019 Dec; 322():113065. PubMed ID: 31536728
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Connexin 30 Deficiency Attenuates Chronic but Not Acute Phases of Experimental Autoimmune Encephalomyelitis Through Induction of Neuroprotective Microglia.
    Fang M; Yamasaki R; Li G; Masaki K; Yamaguchi H; Fujita A; Isobe N; Kira JI
    Front Immunol; 2018; 9():2588. PubMed ID: 30464764
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Microglia pre-activation and neurodegeneration precipitate neuroinflammation without exacerbating tissue injury in experimental autoimmune encephalomyelitis.
    Wimmer I; Scharler C; Zrzavy T; Kadowaki T; Mödlagl V; Rojc K; Tröscher AR; Kitic M; Ueda S; Bradl M; Lassmann H
    Acta Neuropathol Commun; 2019 Jan; 7(1):14. PubMed ID: 30704526
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Surfen, a proteoglycan binding agent, reduces inflammation but inhibits remyelination in murine models of Multiple Sclerosis.
    Warford JR; Lamport AC; Clements DR; Malone A; Kennedy BE; Kim Y; Gujar SA; Hoskin DW; Easton AS
    Acta Neuropathol Commun; 2018 Jan; 6(1):4. PubMed ID: 29301568
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Atf6α deficiency suppresses microglial activation and ameliorates pathology of experimental autoimmune encephalomyelitis.
    Ta HM; Le TM; Ishii H; Takarada-Iemata M; Hattori T; Hashida K; Yamamoto Y; Mori K; Takahashi R; Kitao Y; Hori O
    J Neurochem; 2016 Dec; 139(6):1124-1137. PubMed ID: 27333444
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Timing of treatment with an endogenous opioid alters immune response and spinal cord pathology in female mice with experimental autoimmune encephalomyelitis.
    Patel C; Zagon IS; Pearce-Clawson M; McLaughlin PJ
    J Neurosci Res; 2022 Feb; 100(2):551-563. PubMed ID: 34821408
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.